|20th January 2021||Oliver Christian Bennett||4,399||Open or private sale||$4.49||$19,752.39|
|13th January 2021||Hove Caroline F. Van||1,973||Open or private sale||$4.71||$9,300.52|
|12th January 2021||Keith J Sullivan||125,000||Grant/award etc.||$0.00|
|7th January 2021||Oliver Christian Bennett||3,665||Payment by withholding||$4.26||$15,612.90|
|11th November 2020||Kevin C Oboyle||16,306||Disposition due to a tender of shares in a change of control transaction||$30.75||$501,409.50|
|8th November 2020||Hove Caroline F. Van||100,000||Grant/award etc.||$0.00|
|12th October 2020||Paul Sean Little||50,000||Grant/award etc.||$0.00|
|12th October 2020||Oliver Christian Bennett||50,000||Grant/award etc.||$0.00|
|3rd September 2020||Paul Sean Little||5,763||Payment by withholding||$3.54||$20,401.02|
|14th July 2020||Keith J Sullivan||500,000||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
Sientra, Inc. engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra,. AlloX2, Dermaspan, Softspan and BIOCORNEUM.